Evren Alici

Head of Cell and Gene Therapy Group, Department of Medicine • Karolinska Institutet

Evren Alici, who received his MD at Ege University in 1999 and his PhD from Karolinska Institutet in 2006, focuses his research on natural killer cells, multiple myeloma, lentiviral and retroviral gene transfer, stem cell transplantation, and immunology.

His main research interests involve the generation and testing of genetically engineered NK cells, including chimeric receptors and CAR-NK cells, targeting multiple antigens. The projects undertaken also aim to investigate the effectiveness of small molecules and oncolytic viruses in enhancing NK cell reactivity against tumour cells both in vivo and in vitro. Additionally, he and his team are working on customizing plasmids and viral vectors to optimize gene transfer into immune cells.

Also speaking

Takis Athanasopoulos

Chief Executive Officer, Gene & Cell Ltd., Vice President, Gene Therapy Research & Vector Technology • ViGeneron

Michal Besser

Chief Technology Officer, Davidoff Cancer Center • Rabin Medical Center

Lindsay Davies

Chief Scientific Officer • NextCell Pharma

Event Info


Sponsorship Opportunities Waiting List

Take a look at the sample attendee list for Advanced Therapies Europe 2023 here.


Find out more about partnering at Advanced Therapies Europe.